Statistics for Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Total visits
| views | |
|---|---|
| Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 | 248 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 1 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| annrheumdis-2016-209709.pdf | 256 |
| java.util.UUID:9d61c13e-c2e6-4d2b-908d-49ad7b843418 | 63 |
| java.util.UUID:a6de6bf5-9033-465c-a5df-1a088538b3c9 | 6 |
| java.util.UUID:fcb37a8a-d62a-42da-9341-5c0c2c8416c6 | 6 |
Top country views
| views | |
|---|---|
| United States | 190 |
| Germany | 16 |
| United Kingdom | 5 |
| Ukraine | 5 |
| Russia | 4 |
| Canada | 2 |
| Israel | 1 |
| Malaysia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 49 |
| Fairfield | 30 |
| Houston | 19 |
| Ann Arbor | 18 |
| Kiez | 14 |
| Jacksonville | 7 |
| Kiev | 5 |
| San Francisco | 5 |
| Cambridge | 4 |
| Saint Petersburg | 3 |
| Gunzenhausen | 2 |
| London | 2 |
| Mountain View | 2 |
| Toronto | 2 |
| Washington | 2 |
| Abingdon | 1 |
| Baltimore | 1 |
| Brooklyn | 1 |
| Chicago | 1 |
| Colchester | 1 |
| Flemington | 1 |
| Indianapolis | 1 |
| Kansas City | 1 |
| Lake Mary | 1 |
| Moscow | 1 |
| Norwalk | 1 |
| Philadelphia | 1 |
| Scottsdale | 1 |
| Seremban | 1 |
| Stockholm | 1 |